Agendia BV Announces Study Showing Molecular Subtyping Can Improve Breast Cancer Treatment
AMSTERDAM--(BUSINESS WIRE)--In findings that may eventually change the way breast cancer is evaluated and treated, a new study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of a specific breast cancer, compared to the use of conventional IHC-FISH pathology tests. The prospective observational study of 426 patients was recently published online by the Annals of Surgical Oncology. It concludes that the BluePrint assay, from Dutch molecular diagnostics company Agendia, may be a better guide than IHC-FISH tests in making decisions about how to treat early-stage breast cancer before surgery.
Help employers find you! Check out all the jobs and post your resume.